Acute lymphoblastic leukemia (ALL), a cancer of the blood, occurs when immature white blood cells continuously multiply in bone marrow, which disrupts production of normal blood cells. Nirali Shah, M.D., Staff Clinician in the Pediatric Oncology Branch, is leading a pilot study of a new drug combination for children, adolescents and young adults with relapsed ALL. A combination of chemotherapy drugs known by the regimen UK ALL R3 is one of the most successful treatments for relapsed ALL. In this study, standard vincristine will be replaced with Marqibo, a new formulation of this drug that allows for dose intensification, and will be used in combination with UK ALL R3. Investigators hope the new drug combination will be safe for children with relapsed ALL and will lead to better outcomes. For more information on this trial, visit: https://ccr.cancer.gov/pediatric-oncology-branch/nirali-n-shah.
Posted on Thu, 04/20/2017